Wednesday, July 15, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

Biden picks Dr. Rahul Gupta to lead Federal Drug Policy during overdose crisis

Former West Virginia health commissioner Dr. Rahul Gupta will lead President Joe Biden’s response to the deadliest overdose crisis in recorded history.

The Biden administration is officially tapping Dr. Rahul Gupta as director of the Office of National Drug Control Policy, a White House spokesperson confirmed to Filter. Gupta became a nationally recognized health policy expert during his role as West Virginia’s public health commissioner from 2015 to 2018, where he led the state’s response to its own surging overdose crisis.

Gupta will replace Regina LaBelle, the ONDCP’s current acting director, if confirmed by the Senate. He directed Filter’s request for comment to an ONDCP spokesperson.

Source: Filter Magazine

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Videos

Policy Shift in Peptide Regulation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...

Read more

Join Our Newsletter!